Nilda Mesa Sells 258 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 258 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total transaction of $150,137.94. Following the completion of the transaction, the director owned 5,028 shares in the company, valued at approximately $2,925,944.04. This trade represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $2.20 on Wednesday, reaching $579.54. The stock had a trading volume of 306,229 shares, compared to its average volume of 483,395. The company has a market cap of $24.60 billion, a price-to-earnings ratio of 21.39, a P/E/G ratio of 1.80 and a beta of 0.60. The firm’s fifty day moving average is $553.65 and its two-hundred day moving average is $504.46. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the company posted $6.63 earnings per share. As a group, research analysts forecast that United Therapeutics Corporation will post 27.64 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC grew its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its position in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen increased their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.